Results 71 to 80 of about 11,492 (188)

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

Allergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt, Marie Eggers, Nicola M. Tomas, Friedrich Haag, Friedrich Koch‐Nolte, Boris Fehse, Kristoffer Riecken   +16 more
wiley   +1 more source

Mepolizumab versus placebo for asthma [PDF]

, 2015
Background Mepolizumab is a human monoclonal antibody against interleukin-5 (IL-5), the main cytokine involved in the activation of eosinophils, which in turn causes airway inflammation.
Alvarez-Cuesta, Armentia, Ayars, Ayars, Ayres, Bel, Berger, Blanken, Blanken, Boever, Boulet, Bousquet, Bousquet, Braman, Brown, Bryant, Bryant, Buhl, Buhl, Buhl, Bush, Busse, Busse, Buttner, Caffarelli, Castro, Castro, Chandra, Chervinsky, Clavel, Corren, Corren, Cruz, Cullell-Young, Djukanovic, Ebner, Eckman, El-Nawawy, Fahy, Fahy, Finn, Flood-Page, Flood-Page, Flood-Page, Flood-Page, Frew, Fuhlbrigge, Garcia, Gauvreau, Gauvreau, Gauvreau, Gauvreau, Gevaert, Gibson, Gordon, Greenberg, Gupta, Haldar, Haldar, Haldar, Han, Hanania, Hanania, Hanania, Hill, Hodsman, Holgate, Hoshino, Humbert, Humbert, Humbert, Jacquemin, Jutel, Kandane-Rathnayake, Kang, Kay, Kips, Kon, Kopp, Kopp, Krishnan, Kulus, Lanier, Lanier, Laviolette, Leckie, Leynadier, Lizaso, Masoli, Massanari, Massanari, Mathur, Menzies-Gow, Menzies-Gow, Metzger, Milgrom, Milgrom, Modlin, Moss, Nair, Nair, Nair, Niven, Noga, Noga, Noonan, Oba, Oh, Ohashi, Ohman, Ohta, Ong, Ortega, Ortega, Parker, Patel, Pauli, Pavord, Pavord, Phipps, Piper, Prieto, Pui, Rensen, Rose, Sakamoto, Scheerens, Scheerens, Siergiejko, Silk, Silkoff, Simoes, Singh, Slavin, Soler, Sorkness, Sthoeger, Sugaya, Swanson, Szymaniak, Tanaka, Terr, Vignola, Wark, Wenzel, Wenzel, Wu, Zetterstrom, Zhu, Zielen   +149 more
core   +2 more sources

Comorbid Chronic Rhinosinusitis and Asthma: Shared Risk Factors and Treatment Implications—An EAACI Task Force Report

Allergy, EarlyView.
ABSTRACT Chronic rhinosinusitis (CRS) and asthma are prevalent conditions that often coexist. These diseases share common inflammatory mechanisms, such as T‐helper cell 2 (T2)‐high inflammation, driven by interleukin (IL)‐4, IL‐5, and IL‐13 cytokines.
Sanna Toppila‐Salmi, Sietze Reitsma, Valérie Hox, Simon Gane, Philippe Gevaert, Juan Maza‐Solano, Alma Helevä, Ida Sulku, Kaisa Santala, Iiris Kangasniemi, Ludger Klimek, Adam Chaker, Aspasia Karavelia, Michael Rudenko, Oliver Pfaar, Laura Van Gerven, Shaari Ariana, Michele Schiappoli, Marie Lundberg, Jan Hagemann, Ibon Eguíluz‐Gracia, Andre Moreira   +21 more
wiley   +1 more source

Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria

Future Science OA, 2020
Background: Depression and anxiety are the most common psychiatric comorbidities in chronic spontaneous urticaria (CSU). Omalizumab is a monoclonal antibody approved for CSU treatment. We evaluated the prevalence of anxiety and depression in CSU patients
Laura Diluvio, Arianna Piccolo, Francesco Marasco, Laura Vollono, Caterina Lanna, Barbara Chiaramonte, Cinzia Niolu, Elena Campione, Luca Bianchi   +8 more
doaj   +1 more source

Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT): the role of anti-IgE in severe paediatric eczema: study protocol for a randomised controlled trial. [PDF]

, 2017
The evidence for systemic treatments for severe childhood eczema is limited and largely based on extrapolation of data from adult studies. Current therapies are often immunosuppressant and may be associated with both short- and long-term side effects ...
Chen, Tao
core   +1 more source

IgE-Related Chronic Diseases and Anti-IgE-Based Treatments

Journal of Immunology Research, 2016
IgE is an immunoglobulin that plays a central role in acute allergic reactions and chronic inflammatory allergic diseases. The development of a drug able to neutralize this antibody represents a breakthrough in the treatment of inflammatory pathologies ...
Arnau Navinés-Ferrer, Eva Serrano-Candelas, Gustavo-J Molina-Molina, Margarita Martín   +3 more
doaj   +1 more source

IgE autoantibodies and their association with the disease activity and phenotype in Bullous Pemphigoid: a systematic review [PDF]

, 2017
Bullous Pemphigoid (BP) is the most common autoimmune skin disease of blistering character. The underlying pathophysiological mechanism involves an immune attack, usually by IgG class autoantibodies, on the autoantigen BP 180/BPAg2, which is a type XVII ...
Fairclough, Lucy C., Hadjikyriacou Saniklidou, Ariadne, Tighe, Patrick J., Todd, Ian   +3 more
core   +2 more sources

A Case for Anti‐IgE Vaccination

Allergy, EarlyView.
ABSTRACT Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high‐affinity receptor FcεRI on mast cells and basophils, where allergen‐induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research.
Paul Engeroff, Zahra Gharailoo, Monique Vogel, Martin F. Bachmann   +3 more
wiley   +1 more source

Omalizumab controls surface phenotypes of dendritic cells and monocytes in asthma

Journal of Allergy and Clinical Immunology: Global
Background: Omalizumab can provide clinical benefits to a fraction of moderate-to-severe asthma patients. However, the mechanisms of action of omalizumab have not been fully understood.
Agnes Yang, BS, Laurie Baert, PhD, Katherine Upchurch, PhD, Mark Millard, MD, Matthew Wiest, PhD, Chao Gu, PhD, HyeMee Joo, PhD, SangKon Oh, PhD   +7 more
doaj   +1 more source

Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation

Фармакоэкономика, 2020
Objective – to conduct a pharmacoeconomic analysis of using omalizumab, mepolizumab and reslizumab in the treatment of patients with uncontrolled moderate and severe atopic asthma in the healthcare setting of the Russian Federation.Materials and Methods.
S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev   +2 more
doaj   +1 more source